Qva149 Improves Lung Function, Dyspnea, And Health Status Independent Of Previously Prescribed Medications And Copd Severity: A Subgroup Analysis From The Shine And Illuminate Studies

Background: QVA149 is a dual bronchodilator combining the long-acting beta 2-agonist(LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium, for maintenance treatment of COPD. This post hoc analysis evaluated the improvements in lung function, dyspnea, and health status in subgroups of patients based on prior medication use, disease severities, baseline cough score, and baseline rescue medication use, achieved with QVA149 compared with placebo and other active comparators in 2 phase III clinical studies.Methods: In both the SHINE (NCT01202188) and ILLUMINATE (NCT01315249) studies, symptomatic patients aged >= 40 years with moderate-to-severe COPD were randomized to once-daily QVA149 (110/50 mu g), indacaterol (150 mu g), glycopyrronium (50 mu g), tiotropium (18 mu g), or placebo (2:2:2:2:1) and once-daily QVA149 (110/50 mu g) or twice-daily salmeterol/fluticasone ([SFC]; 50/500 mu g), respectively for 26 weeks. Here, we present the improvements in lung function, transition dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) total score by prior medication use and COPD disease severity separately from both studies.Results: In total, 2144 and 523 patients were randomized in the SHINE and ILLUMINATE studies; 89.1% and 82.6%, respectively, completed the study. QVA149 showed significant improvements in lung function compared with placebo (SHINE study) and SFC (ILLUMINATE study) regardless of prior medication, disease severity, baseline cough score, and rescue medication use. TDI and SGRQ total scores were also improved with QVA149 compared with placebo and SFC in most of the analyzed subgroups.Conclusions: QVA149 showed improvements in lung function, dyspnea, and health status in both moderate and severe COPD patients independent of previous medication use and baseline cough score.